{
    "clinical_study": {
        "@rank": "33461", 
        "acronym": "MAGIC-P", 
        "arm_group": [
            {
                "arm_group_label": "Group A: standard regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in the  group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an endoscopist-blinded, prospective, multicenter study involving  adult outpatients\n      aiming at evaluating whether sodium picosulphate/magnesium citrate split dosing is\n      associated to higher efficacy and acceptability in comparison to the standard dose regimen\n      in bowel cleansing before colonoscopy"
        }, 
        "brief_title": "PMC Split Preparation for Colon Cleansing", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Colon Cleansing", 
        "detailed_description": {
            "textblock": "Picosulphate/magnesium citrate is a very effective, safe and tolerated low-volume\n      preparation for colon cleansing. This study evaluates whether split dosing is associated to\n      a further increase  in efficacy and acceptability in comparison to the standard dose\n      regimen. This is a multicenter, randomized, single-blind study performed in 15 endoscopic\n      services in Italy.\n\n      Adult outpatients undergoing colonoscopy  will receive  picosulphate/magnesium citrate\n      either in the standard dosing (group A, two sachets the day before endoscopy), or in the\n      split  dosing (group B, the second dose in the morning of colonoscopy). Bowel cleansing\n      will be assessed using the Boston Scale (BBPS) and rated as adequate  if >2 in each segment.\n      Patient acceptance, satisfaction, and related symptoms will be also recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult outpatients\n\n          -  aged 18-85 yr\n\n          -  undergoing elective colonoscopy\n\n        Exclusion Criteria:\n\n          -  previous colon resection,\n\n          -  ileus,\n\n          -  intestinal obstruction,\n\n          -  toxic megacolon,\n\n          -  severe heart failure (NYHA Class III or IV),\n\n          -  acute cardiovascular disease,\n\n          -  uncontrolled arterial hypertension (systolic pressure >170 mmHg, diastolic pressure\n             >100 mmHg),\n\n          -  severe liver cirrhosis (Child-Pugh score C),\n\n          -  renal failure (creatinine clearance<30 mL/minute),\n\n          -  ascites,\n\n          -  phenylketonuria,\n\n          -  glucose-6-phosphate dehydrogenase deficiency,\n\n          -  pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "862", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909219", 
            "org_study_id": "PMC split"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A: standard regimen", 
                "Group B"
            ], 
            "description": "Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate", 
            "intervention_name": "Sodium picosulphate/magnesium Citrate", 
            "intervention_type": "Drug", 
            "other_name": "Citrafleet"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Picosulfate sodium", 
                "Magnesium citrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "preparation, cleansing, colon", 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy", 
                    "zip": "I-20157"
                }, 
                "name": "Luigi Sacco University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial Comparing Efficacy and Acceptability of Split and Standard Dose Sodium Picosulphate/Magnesium Citrate for Bowel Cleansing Prior to Colonoscopy: the MAGIC-P Multicenter Study", 
        "overall_official": {
            "affiliation": "Sacco Huniversity Hospital", 
            "last_name": "Gianpiero Manes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study was the quality of overall colon cleansing, assessed by the endoscopist. Colon cleansing quality was dichotomized as \"adequate\" (score > 2 in each colon segment) or \"inadequate\" (score < 2 in one or more colon segments", 
            "measure": "Rate of adequate colon cleansing", 
            "safety_issue": "No", 
            "time_frame": "24 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909219"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Luigi Sacco University Hospital", 
            "investigator_full_name": "Gianpiero Manes", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The overall tolerance of the preparation  and the severity of  symptoms during the preparation period will be rated on a scale ranging from 0 (no discomfort) to 3 (severe discomfort).  Patient acceptance of the preparation will be evaluated by a questionnaire with a 5-point scale ranging from 1 (worse)  to 5 (best), assessing interference with daily activity, palatability, easiness in  taking the product and the adjunctive clear fluid, and taste of product. Moreover, a nurse  will ask the patient whether s/he have completed the prescribed regimen: compliance will be defined as poor  for patients who consume less than 75% of product. Willingness to repeat the same preparation in the future will be also recorded.", 
            "measure": "Patients' acceptance, tolerability and compliance  to the cleansing regimen", 
            "safety_issue": "Yes", 
            "time_frame": "24 hrs"
        }, 
        "source": "Luigi Sacco University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Luigi Sacco University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}